https://pharmacopedia.wiki/index.php?action=history&feed=atom&title=Omega-3-acid_Ethyl_EstersOmega-3-acid Ethyl Esters - Revision history2026-05-28T06:48:16ZRevision history for this page on the wikiMediaWiki 1.46.0-betahttps://pharmacopedia.wiki/index.php?title=Omega-3-acid_Ethyl_Esters&diff=6499&oldid=prevMDElliottMD: home-claude punt-list stub, Top 300 #2222026-05-23T04:41:14Z<p>home-claude punt-list stub, Top 300 #222</p>
<p><b>New page</b></p><div>Omega-3-acid ethyl esters is a prescription fish-oil-derived preparation containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as their ethyl esters, indicated as an adjunct to diet for adults with severe hypertriglyceridemia (triglycerides at least 500 mg/dL)<ref name="lovaza-label">FDA Prescribing Information, Lovaza (omega-3-acid ethyl esters), GlaxoSmithKline, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021654s018lbl.pdf</ref>. It is distinct from [[Icosapent Ethyl]] (Vascepa), which is purified EPA ethyl ester only; the cardiovascular-outcomes evidence supporting icosapent ethyl in REDUCE-IT does not extend to mixed EPA+DHA preparations, and the STRENGTH trial of a related carboxylic-acid omega-3 formulation was stopped early for futility{{citation needed}}.<br />
<br />
{{MedTemplate<br />
| generic = Omega-3-acid ethyl esters<br />
| brand = Lovaza, Omtryg<br />
| structure =<br />
| classes = [[:Category:Omega-3_fatty_acids|Omega-3 fatty acid]], [[:Category:Lipid-lowering_agents|Lipid-lowering agent]]<br />
| uses = <vote slug="severe-hypertriglyceridemia-use">Severe hypertriglyceridemia (TG at least 500 mg/dL)</vote><br />
| starting_dose = 4 g PO daily (as 4 x 1 g capsules once daily, or 2 capsules BID)<br />
| preparations = 1 g soft gelatin capsules containing ~465 mg EPA + ~375 mg DHA as ethyl esters<br />
| fda_max = 4 g/d<br />
| pill_id =<br />
| routes = Oral<br />
| onset = Triglyceride lowering at 2-4 weeks; max at 8 weeks<br />
| duration = Daily dosing<br />
| halflife = Not well characterized; tissue incorporation over weeks<ref name="lovaza-label" /><br />
| bioavailability = Improved with food<ref name="lovaza-label" /><br />
| pregnancy = Limited human data{{citation needed}}<br />
| legal = [[USLegal:Prescription only|Rx-only]] in US<br />
| mechanism = <vote slug="lovaza-mech-claim">Omega-3-acid ethyl esters lower serum triglycerides primarily by reducing hepatic VLDL-triglyceride synthesis and increasing fatty-acid oxidation; LDL may rise modestly in the mixed EPA+DHA preparations, unlike the pure-EPA icosapent ethyl.</vote> The EPA+DHA mix is biochemically and clinically distinct from icosapent ethyl<ref name="lovaza-label" />.<br />
}}<br />
<br />
== References ==<br />
<references /></div>MDElliottMD